PMID- 29077166
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 19
DP  - 2017 Oct
TI  - Correlation between RAR-beta expression in lung squamous cell carcinoma tissues and 
      prognosis.
PG  - 4304-4310
LID - 13499 [pii]
AB  - OBJECTIVE: To explore the retinoic acid receptor-beta (RAR-beta) expression in lung 
      squamous cell carcinoma (LSCC) tissues and its prognosis. PATIENTS AND METHODS: 
      SP assay was used to detect the RAR-beta expression in 100 cases of surgically 
      resected LSCC tissues and 20 cases of peritumoral normal lung tissues, and 
      prognosis follow-up was conducted. RESULTS: The overall positive expression rate 
      of RAR-beta was 54.00%, which was not correlated with age, gender, phase and 
      pathological type (p>0.05). Stratified analysis showed that the prognosis of 
      patients with positive IRAR-beta expression in phase I was significantly better than 
      that of those with negative IRAR-beta expression, in which the median survival times 
      were 31 and 22 months respectively (p=0.022). In contrast, the prognosis of 
      patients with negative RAR-beta expression was better than that of those with 
      positive RAR-beta expression in phase II and III A. The median survival times were 
      23 and 16 months respectively in phase II p = 0.008, and 19 and 7 months 
      respectively in phase III A (p=0.019). CONCLUSIONS: RAR-beta is expressed in LSCC 
      tumor tissues. RAR-beta expression, which is not significantly correlated with the 
      clinicopathological characteristics of patients, affects the postoperative 
      survival of LSCC patients in phase I and II-III A dually. RAR-beta expression state 
      is one of the independent factors for the prognosis of LSCC patients.
FAU - Hou, P-Z
AU  - Hou PZ
AD  - Department of Oncology Radiotherapy, Henan Provincial People's Hospital, 
      Zhengzhou, Henan Province, China. mazhengquan1103@163.com.
FAU - Jian, G
AU  - Jian G
FAU - Ma, Z-Q
AU  - Ma ZQ
FAU - Xu, Y
AU  - Xu Y
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (retinoic acid receptor beta)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Squamous Cell/diagnosis/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/diagnosis/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptors, Retinoic Acid/*biosynthesis
MH  - Survival Analysis
EDAT- 2017/10/28 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/10/28 06:00
PHST- 2017/10/28 06:00 [entrez]
PHST- 2017/10/28 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
AID - 13499 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Oct;21(19):4304-4310.